bluebird bio (BLUE) Opens Phase 3 Study of LentiGlobin in Patients with Transfusion-Dependent Beta-Thalassemia
Tweet Send to a Friend
bluebird bio, Inc. (Nasdaq: BLUE) today announced the opening of HGB-207, a Phase 3, global, multi-center study in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
